AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021
Sep 1, 2021
29977_dirs_2021-09-01_de6f0dd3-0002-44f1-a5ac-9023b86b21b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-31
Reporting Person: Landry Robert E (EVP Finance CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-31 | Common Stock | M | 1000 | $555.67 | Acquired | 26903 | Direct |
| 2021-08-31 | Common Stock | F | 917 | $675.03 | Disposed | 25986 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-31 | Non-Qualified Stock Option (right to buy) | $555.67 | M | 1000 | Disposed | 2025-12-16 | Common Stock (1000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 229 | Indirect |
Footnotes
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3